Current calls, week 9, 2018

Published 2018-03-02 09:04. Updated 2018-03-05 14:36

Tips from KI Grants Office about current calls

Swedish and nordic grants

Hjärt-Lungfonden - Prins Daniels forskningsanslag till yngre forskare

Syftar till att främja återväxten av yngre forskare genom att bland annat utlysa anslag till dem. Medel omfattar SEK 2 miljoner per år under tre år.

Closing date: 19 March 2018

Hjärt-Lungfonden - Prins Daniels forskningsanslag till yngre forskare

Artificiell intelligens för bättre hälsa – Vinnova

 Syftar till att förbättra folkhälsan, vården eller omsorgen i Sverige med hjälp av artificiell intelligens. Den totala budgeten är SEK 20 miljoner. 

Closing date: 20 March 2018

 Artificiell intelligens för bättre hälsa – Vinnova 

Project grants for the development of methods for the replacement, reduction and refinement of animal testing - Swedish Research Council | Vetenskapsrådet

Support projects that promote the development of methods for the replacement, reduction and refinement of animal experiments.Grants are worth between SEK 400,000 and SEK 2,5 million per year for the duration of one to three years.

Closing date: 20 March 2018 

Project grants for the development of methods for the replacement, reduction and refinement of animal testing - Swedish Research Council | Vetenskapsrådet 

Projektbidrag inom farmaci - Vetenskapsrådet

Detta bidrag stöder forskningsprojekt inom farmaci.

Closing date: 20 March 2018 

Projektbidrag inom farmaci - Vetenskapsrådet 

Grants for research and development projects - Stiftelsen Promobilia

Promote the development and production of technical aids that enable disabled persons to have a more active life. Grants are worth between SEK 100,000 and SEK 500,000 each.

Closing date: 22 March 2018

Grants for research and development projects - Stiftelsen Promobilia

Projekt- och resebidrag - Hudfonden

Detta stöder medicinsk forskning inom dermatologi och venereologi. Den totala budgeten är SEK 8 miljoner per år. Projektanslag kan uppgå till högst tre år.

Closing date: 31 March 2018

Projekt- och resebidrag - Hudfonden 

Forskningsanslag - Linnéa and Josef Carlssons Foundation | Linnéa och Josef Carlssons Stiftelse

Stöder forskning som syftar till att förebygga, bekämpa och lindra sjukdomar, utvecklingsstörningar och skador av invalidiserande natur hos barn och ungdomar med neurologiska handikapp. Bidrag uppgår till SEK 1 miljon.

Closing date: 31 March 2018

Forskningsanslag - Linnéa and Josef Carlssons Foundation | Linnéa och Josef Carlssons Stiftelse 

Stipendier för forskarkurser och kongresser - Apotekarsocieteten | Swedish Pharmaceutical Society 

Stöder deltagande i forskarkurser, kongresser och liknande, med läkemedelsinriktning. Den totala budgeten uppgår till SEK 1.09 miljoner.

Closing date: 31 March 2018

Stipendier för forskarkurser och kongresser - Apotekarsocieteten | Swedish Pharmaceutical Society 

FoU-anslag - J. Gustaf Richert stiftelse Sweco

Stipendier delas ut för att främja forskning, undervisning och utbildning inom områdena miljövård, energi, samhällsbyggnad och transportteknik, bland annat med avseende på teknisk-ekonomisk analys inom nämnda områden.

Closing date: 3 April 2018

FoU-anslag - J. Gustaf Richert stiftelse Sweco 

European grants

Swiss Bridge award -- Swiss Cancer League | Krebsliga Schweiz, CH and other funders

This supports cancer research in Europe. The focus topic for the 2018 award is immuno-oncology biomarkers. Researchers holding a PhD or MD and independent position at a hospital, university or research institute in Europe may apply. Applicants should be under the age of 45 years.

The total budget is CHF 500,000 to fund up to three awards. Grants are worth up to CHF 300,000 each.

Closing date: 30 April 2018

Swiss Bridge award -- Swiss Cancer League | Krebsliga Schweiz, CH and other funders 

Innovation prize -- Universal Biotech, FR

This recognises innovative digital-, medical- and biotechnological projects within the field of life sciences. The following types of projects are accepted:

•drugs, molecules and vaccines;

•medical devices, services and diagnostics;

•health non-contact infrared thermometer, e-health, applications and connected tools.

Academic researchers in the field of life sciences, and representatives from young start-ups and companies less than eight years old, may apply. Projects will each be awarded a grant and a year of consulting services, with a combined value of €30,000.

Closing date: 30 April 2018

Innovation prize -- Universal Biotech, FR 

Research fellowship -- European Academy of Dermatology and Venereology, EUR

This enables young scientists to receive advanced training on basic or clinical research in dermatology or venereology in a high standard clinical or research centre at a country other than their own.

Dermatologists, venereologists, residents in dermatology-venereology and junior post-doctoral scientists with a special interest in dermatology or venereology may apply. Applicants must come from Europe, be under 40 years of age and have previous published experience in the field of research they are planning to engage in or have a track record in skin research documented by their publication records.

Fellowships are worth up to €30,000 each over 12 months and cover travel, insurance costs and living expenses.

Closing date: 30 April 2018

Research fellowship -- European Academy of Dermatology and Venereology, EUR 

Dermatology and venereology project funding -- European Academy of Dermatology and Venereology, EUR

This supports projects involving several experts groups from European countries and benefiting patients with skin diseases. Funding is worth up to €100,000 per project and may be used to cover salaries, equipment, facilities and administrative costs as well as travel and publication costs.

Closing date: 30 April 2018

Dermatology and venereology project funding -- European Academy of Dermatology and Venereology, EUR 

NEXT start-up grant -- European Society of Intensive Care Medicine, EUR

This grant enables the professional development of newly board-certified intensive care physicians to develop their independent research programmes in the field of intensive care and emergency medicine. Research programme proposals may rely on approaches ranging from basic cellular responses to outcome research, and may include clinical applications as well as translational science.

Closing date: 1 May 2018

NEXT start-up grant -- European Society of Intensive Care Medicine, EUR 

Translational research fellowships -- European Society for Medical Oncology, EUR

These enable young researchers to train in translational research at European institutions of excellence, and to develop specific high-quality translational research projects in oncology. Applicants must be

• ESMO members, 40 years of age or under;

• oncologists with at least one year experience in medical, radiation or surgical oncology and currently engaged in cancer research or clinical oncology practice;

Fellowships are worth €40,000 for one year, with the possibility of an additional €40,000 for a second year. Host institutions receive €1,000 towards administrative costs.

Closing date: 3 May 2018

Translational research fellowships -- European Society for Medical Oncology, EUR 

US grants

Federal Funding agencies

Serious Adverse Drug Reaction Research (R01, R21): NIH

This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions (ADRs), particularly those that are idiosyncratic. Potential areas of study include, but are not limited to, basic research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the development of therapies and interventions to treat and prevent serious ADRs.

Closing date: 30 days prior to the application due date (Letter of Intent), June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019 (Application Due Date(s)), by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-16-274 (R21), PAR-16-275 (R01)

Serious Adverse Drug Reaction Research (R21): NIH  

Serious Adverse Drug Reaction Research (R01): NIH

Modelling of infectious disease agent study research projects (R01): NIH

The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.  

Closing date: Standard dates apply, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-17-267

Modelling of infectious disease agent study research projects (R01): NIH 

Advancing Erythroid Cell Biology (R01): NIH

This funding opportunity announcement (FOA) supports research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components function to achieve normal erythropoiesis. Research should identify fundamental mechanisms of haematologic development and cell differentiation. The goals of this program are to 1) use the erythroid cell system to test hypotheses regarding coordination of gene expression and interaction of proteins during hematologic development and differentiation and 2) to elucidate structure-function relationships in normal and diseased erythroid blood cell states that will inform biology of other cell types.

Closing date: Standard dates apply, by 5:00 PM local time of applicant organization until January 8, 2019.

Funding Opportunity Announcement (FOA): PA-16-039

Advancing Erythroid Cell Biology (R01): NIH 

Advances in Polycystic Kidney Disease (R01): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of Polycystic Kidney Disease (PKD), in both its autosomal dominant and autosomal recessive forms.  The ultimate aim is to facilitate PKD-related research studies, which will provide the basis for new therapeutic approaches.

Closing date: Standard dates apply, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PA-16-159

Advances in Polycystic Kidney Disease (R01): NIH 

 

Foundations

Muscular Dystrophy Association

Development grants

These development grants provide seed money to help senior postdoctoral researchers on the brink of becoming independent researchers to conduct projects on neuromuscular disease. Projects should aim to: a) accelerate therapy development for the muscle diseases, including new target identification, target validation, screening for new therapeutic molecules that hit validated targets, and addressing a need of the neuromuscular research field, as well as clinical research projects; b) result in new understanding of disease aetiology and pathogenesis in neuromuscular disorders where these are not well understood. Applicants must hold a Doctor of Medicine (M.D.), Doctor of Philosophy (Ph.D), Doctor of Science (D.Sc.) or equivalent degree (i.e. D.O.), be qualified to conduct a program of original research under the supervision of an independent investigator and be no more than 60 months from receiving their most recent advanced degree (e.g. Ph.D, M.D. or equivalent).

Research grants

These research grants support research to accelerate progress towards understanding and treating neuromuscular disease. Projects that may result in new understanding of disease etiology and pathogenesis in neuromuscular disorders where these are not well understood are welcomed. Possible other research themes include: new target identification; target validation; screening for new therapeutic molecules that hit validated targets; addressing a need of the neuromuscular research field, such as developing novel animal cell models of the disease, or developing new technologies; clinical research. Applicants must hold a Doctor of Medicine (M.D.), Doctor of Philosophy (Ph.D), Doctor of Science (D.Sc.) or equivalent degree (i.e. D.O.), be a professional or faculty member (professor, associate professor or assistant professor).

Closing date: June 15 2018, by 11:59 p.m. ET (Letter of Intent); July 15, by 5 p.m. ET (Full Proposal)

Muscular Dystrophy Association 

Links